ACA
BBIO icon

American Capital Advisory’s BridgeBio Pharma BBIO Stock Holding History

American Capital Advisory’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$298 Buy
4
+2
+100% +$140 ﹤0.01% 1033
2026
Q1 		$149 Hold
2
– – ﹤0.01% 1055
2025
Q4 		$153 Buy
+2
New +$131 ﹤0.01% 947

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

American Capital Advisory's BBIO Position: Q2 2026 in Review

American Capital Advisory increased its BridgeBio Pharma (BBIO) stake by 100% in Q2 2026, buying an estimated $140 and bringing the position to 4 shares worth $298. The position accounts for ﹤0.01% of the portfolio, ranked #1033.

American Capital Advisory first reported a position in BBIO in Q4 2025 and has held it in 3 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • American Capital Advisory held 4 shares of BridgeBio Pharma worth $298 as of Q2 2026.
  • American Capital Advisory bought 2 BridgeBio Pharma shares in Q2 2026, an estimated $140.
  • BridgeBio Pharma made up ﹤0.01% of American Capital Advisory's portfolio in Q2 2026, its #1033 holding.
  • American Capital Advisory first reported a position in BridgeBio Pharma in Q4 2025 and has held it in 3 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on American Capital Advisory's 13F filing for Q2 2026, filed 28 Jul 2026.